Publications by authors named "Axel Dalhoff"

Claim this Profile
A
Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets?
Axel Dalhoff

Infection· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective toxicity of antibacterial agents-still a valid concept or do we miss chances and ignore risks?
Axel Dalhoff

Infection· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative evaluation of eight in vitro pharmacodynamic models of infection: Activity of moxifloxacin against Escherichia coli and Streptococcus pneumoniae as an exemplary example.
Axel Dalhoff, Karen Bowker, Alasdair MacGowan

Int J Antimicrob Agents· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does the use of antifungal agents in agriculture and food foster polyene resistance development? A reason for concern.
Axel Dalhoff

J Glob Antimicrob Resist· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates.
Andreas Vente, Christine Bentley, Mark Lückermann, Paul Tambyah, Axel Dalhoff

Antimicrob Agents Chemother· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections.
Max Taubert, Mark Lückermann, Andreas Vente, Axel Dalhoff, Uwe Fuhr

Antimicrob Agents Chemother· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seventy-Five Years of Research on Protein Binding.
Axel Dalhoff

Antimicrob Agents Chemother· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.
Max Taubert, Joseph Chiesa, Mark Lückermann, Carsten Fischer, Axel Dalhoff

Antimicrob Agents Chemother· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to the reaction to Dalhoff and Levy: 'Does use of the polyene natamycin as a food preservative jeopardise the clinical efficacy of amphotericin B? A word of concern'.
Axel Dalhoff

Int J Antimicrob Agents· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does use of the polyene natamycin as a food preservative jeopardise the clinical efficacy of amphotericin B? A word of concern.
Axel A H Dalhoff, Stuart B Levy

Int J Antimicrob Agents· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.
Axel Dalhoff

Clin Microbiol Rev· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternative strategies for proof-of-principle studies of antibacterial agents.
Axel Dalhoff, Andrej Weintraub, Carl Erik Nord

Antimicrob Agents Chemother· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ecological impact of MCB3837 on the normal human microbiota.
Mamun-Ur Rashid, Axel Dalhoff, Tobias Bäckström, Linda Björkhem-Bergman, Georgios Panagiotidis

Int J Antimicrob Agents· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of MCB3681 against Clostridium difficile strains.
Mamun-Ur Rashid, Axel Dalhoff, Andrej Weintraub, Carl Erik Nord

Anaerobe· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effect of serum proteins on the antibacterial activity and pharmacodynamics of ceftaroline against Staphylococcus aureus.
Axel Dalhoff, Sabine Schubert

Int J Antimicrob Agents· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrations in the human pancreas.
Sabine Schubert, Axel Dalhoff

Antimicrob Agents Chemother· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global fluoroquinolone resistance epidemiology and implictions for clinical use.
Axel Dalhoff

Interdiscip Perspect Infect Dis· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose.
Florian M E Wagenlehner, Christine M Wagenlehner, Birgit Blenk, Holger Blenk, Sabine Schubert, Axel Dalhoff

Chemotherapy· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine.
Axel Dalhoff, Will Stubbings, Sabine Schubert

Antimicrob Agents Chemother· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study.
Harald Seifert, Axel Dalhoff,

J Antimicrob Chemother· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
Axel Dalhoff, Sabine Schubert

Int J Antimicrob Agents· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Enno Jacobs, Axel Dalhoff, Gisela Korfmann

Int J Antimicrob Agents· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redefining penems.
Axel Dalhoff, Nebojsa Janjic, Roger Echols

Biochem Pharmacol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.
Florian M E Wagenlehner, Martina Kinzig-Schippers, Uwe Tischmeyer, Christine Wagenlehner, Fritz Sörgel, Axel Dalhoff

Int J Antimicrob Agents· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge.
Martina Ulrich, Cordula Albers, Jan-Georg Möller, Axel Dalhoff, Gisela Korfmann

Antimicrob Agents Chemother· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis